Literature DB >> 11672493

Pilot randomized controlled study of dexamphetamine substitution for amphetamine dependence.

J Shearer1, A Wodak, R P Mattick, I Van Beek, J Lewis, W Hall, K Dolan.   

Abstract

AIMS: To test the feasibility of conducting a definitive randomized controlled trial of dexamphetamine substitution for amphetamine dependent people and provide preliminary data.
DESIGN: An open, two-group pre-post randomized controlled trial. PARTICIPANTS: Forty-one long-term, dependent amphetamine users seeking treatment. INTERVENTION: Twenty subjects were offered weekly counselling. Twenty-one subjects were, in addition, prescribed up to 60 mg dexamphetamine daily. MEASUREMENTS: Immunoassay and mass spectrometric urinalysis techniques were used to identify the presence of amphetamine and methylamphetamine in urine. The Opiate Treatment Index and Severity of Dependence Scale were used to collect pre- and post-self-report data. Subjects were screened using the Composite International Diagnostic Interview.
FINDINGS: Reduced street amphetamine use and amphetamine dependence was observed both in subjects prescribed dexamphetamine and subjects receiving counselling only. Treatment subjects appeared more likely to attend counselling.
CONCLUSIONS: A definitive randomized controlled trial of dexamphetamine substitution using the techniques and instruments piloted in this study is feasible. Users appeared to be attracted and retained in substitution treatment. The intervention also appeared to be acceptable to clinicians.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11672493     DOI: 10.1046/j.1360-0443.2001.96912898.x

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  25 in total

1.  Subjective and physiological effects of acute intranasal methamphetamine during d-amphetamine maintenance.

Authors:  Craig R Rush; William W Stoops; Joshua A Lile; Paul E A Glaser; Lon R Hays
Journal:  Psychopharmacology (Berl)       Date:  2010-11-12       Impact factor: 4.530

Review 2.  The need for speed: an update on methamphetamine addiction.

Authors:  Alasdair M Barr; William J Panenka; G William MacEwan; Allen E Thornton; Donna J Lang; William G Honer; Tania Lecomte
Journal:  J Psychiatry Neurosci       Date:  2006-09       Impact factor: 6.186

Review 3.  Human Drug Discrimination: Elucidating the Neuropharmacology of Commonly Abused Illicit Drugs.

Authors:  B Levi Bolin; Joseph L Alcorn; Anna R Reynolds; Joshua A Lile; William W Stoops; Craig R Rush
Journal:  Curr Top Behav Neurosci       Date:  2018

Review 4.  The methamphetamine epidemic: implications for HIV prevention and treatment.

Authors:  Grant Colfax; Steven Shoptaw
Journal:  Curr HIV/AIDS Rep       Date:  2005-11       Impact factor: 5.071

Review 5.  Future pharmacological treatments for substance use disorders.

Authors:  Ariadna Forray; Mehmet Sofuoglu
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

6.  Effects of chronic d-amphetamine administration on the reinforcing strength of cocaine in rhesus monkeys.

Authors:  Paul W Czoty; Jennifer L Martelle; Michael A Nader
Journal:  Psychopharmacology (Berl)       Date:  2010-03-09       Impact factor: 4.530

Review 7.  Pharmacotherapy of amphetamine-type stimulant dependence: an update.

Authors:  Matthew Brensilver; Keith G Heinzerling; Steven Shoptaw
Journal:  Drug Alcohol Rev       Date:  2013-04-25

Review 8.  Pharmacotherapy of methamphetamine addiction: an update.

Authors:  Ahmed Elkashef; Frank Vocci; Glen Hanson; Jason White; Wendy Wickes; Jari Tiihonen
Journal:  Subst Abus       Date:  2008       Impact factor: 3.716

9.  Acute d-amphetamine pretreatment does not alter stimulant self-administration in humans.

Authors:  William W Stoops; Andrea R Vansickel; Joshua A Lile; Craig R Rush
Journal:  Pharmacol Biochem Behav       Date:  2007-04-05       Impact factor: 3.533

Review 10.  Treatment strategies for co-occurring ADHD and substance use disorders.

Authors:  John J Mariani; Frances R Levin
Journal:  Am J Addict       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.